Publications by authors named "Shane Supple"

Claim this Profile
S
Sensitive monitoring of acute promyelocytic leukemia by PML-RARA DNA Q-PCR.
Ivar O Kommers, Paul A Bartley, Bradley Budgen, Sue Latham, Ashanka Beligaswatte, Shane G Supple

Leuk Lymphoma· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atypical presentation of therapy-related acute promyelocytic leukaemia with marrow fibrosis.
Muhajir Mohamed, Harry J Iland, Sharad Sharma, Shane G Supple

Pathology· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Harry J Iland, Marnie Collins, Ken Bradstock, Shane G Supple, Alberto Catalano

Lancet Haematol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT.
Teh-Liane Khoo, Alberto Catalano, Shane Supple, Li Chong, Sue-Ching Yeoh

Leuk Lymphoma· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Harry J Iland, Ken Bradstock, Shane G Supple, Alberto Catalano, Marnie Collins

Blood· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.
Harry Iland, Ken Bradstock, John Seymour, Mark Hertzberg, Andrew Grigg, Shane Supple

Haematologica· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Michael C Heinrich, Heikki Joensuu, George D Demetri, Christopher L Corless, Jane Apperley, Shane G Supple

Clin Cancer Res· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis